secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060399
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing
--------------------------------------------------------------------------------

- Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.
- Cash balance $3.0M at March 31, 2024, down from $8.6M at December 31, 2023.
- Closed private placement for initial $7.25M with potential total of $19.25M from healthcare funds and insiders.
- Received $3M Department of Defense grant recommendation for Phase 1 rhenium obisbemeda trial in pediatric brain cancer.
- Acquired exclusive rights to CNSide leptomeningeal metastases diagnostic; reported positive top-line FORESEE trial data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/0000950170-24-060399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/pstv-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer